Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Zapping away shingles pain: new trial tests pulsed radiofrequency

NCT ID NCT07390279

Symptom relief Sponsor: Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a noninvasive procedure called transcutaneous pulsed radiofrequency can reduce chronic pain from postherpetic neuralgia, a complication of shingles. The procedure delivers electrical pulses through electrodes placed on the skin over the painful area. Researchers will enroll 35 adults with this condition to measure changes in pain intensity and nerve pain symptoms.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Transcutaneous pulsed radiofrequency (a noninvasive procedure using electrical pulses over the painful area)
What this could lead to
If it works, this could offer a new, noninvasive option to reduce chronic pain from shingles without drugs or injections.
What could go wrong
This is a small, early-stage trial with only 35 people, so results may not apply to everyone. The procedure may not provide lasting pain relief.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 35 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Feb 2026

An estimate. Start dates often move.

Expected to finish

Aug 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study will be conducted at the Algology Department of Istanbul Cemil Taşcıoğlu City Hospital, following approval by the institutional ethics committee, and will include patients aged 18 years and older diagnosed with postherpetic neuralgia (PHN) who are scheduled to receive transcutaneous pulsed radiofrequency (TCPRF) treatment in three sessions. Within the scope of the study, the following data will be recorded: age, sex, body mass index (BMI), side of the procedure, history of herpes zoster vaccination (live or recombinant), family history of herpes zoster, immunosuppression status (e.g., HIV infection, malignancy, steroid use), duration of symptoms, dermatome treated with TCPRF, TCPRF-related complications and adverse effects, Visual Analog Scale (VAS) scores, neuropathic pain assessment using the Douleur Neuropathique 4 (DN4) questionnaire, and health-related quality of life assessed using the Short Form-12 (SF-12).

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years * Diagnosis of postherpetic neuralgia (PHN) * No invasive or noninvasive treatment related to PHN (e.g., capsaicin, lidocaine patches) within the past 3 months * Provision of written informed consent Exclusion Criteria: * Patients with a cardiac pacemaker * Known allergy to transcutaneous electrode pads * Active skin infection at the pad application site * Presence of a metallic implant in the treatment area * Circulatory disorders or skin lesions at the treatment site * Inability to maintain appropriate positioning * Inability to communicate effectively * Presence of psychosis or progressive neurological deficits * Pregnancy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic pain are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Chronic Pain chronic pain syndrome Neuralgia, Postherpetic peripheral neuropathy postherpetic neuralgia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic pain Neuropathy Postherpetic neuralgia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Istanbul Prof. Dr. Cemil Taşcioğlu City Hospital

    RECRUITING

    Istanbul, Istanbul, 34000, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.